DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Phase 3

Completed

Conditions: Chronic Migraine

Interventions: Drug: Atogepant

First Posted Date: 2022-01-31

Last Posted Date: 2025-05-16

Lead Sponsor: AbbVie

Target Recruit Count: 75

Registration Number: NCT05216263

Locations: 🇺🇸
Dent Neurologic Institute - Amherst /ID# 241776, Amherst, New York, United States
🇺🇸
Hope Clinical Research /ID# 241772, Canoga Park, California, United States
🇺🇸
Profound Research LLC /ID# 244084, Carlsbad, California, United States

and more 26 locations

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

Conditions: wAMD
Neovascular Age-Related Macular Degeneration (nAMD)
Wet AMD
nAMD
Gene Therapy
AMD

Interventions: Other: No intervention.

First Posted Date: 2022-01-27

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 115

Registration Number: NCT05210803

Locations: 🇺🇸
California Retina Consultants, Santa Barbara, California, United States
🇺🇸
Northern California Retina Vitreous Associates Medical Group Inc, Mountain View, California, United States
🇺🇸
Southeast Retina Center PC, Augusta, Georgia, United States

and more 12 locations

An Observational Study to Assess the Real-World Effectiveness of Upadacitinib in Adult Participants With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2021-12-28

Last Posted Date: 2025-04-29

Lead Sponsor: AbbVie

Target Recruit Count: 97

Registration Number: NCT05170646

Locations: 🇬🇧
Cambridge University Hospitals NHS Foundation Trust /ID# 251706, Cambridge, United Kingdom
🇬🇧
The Royal Wolverhampton NHS Trust /ID# 251708, Wolverhampton, United Kingdom
🇬🇧
Medway NHS Foundation Trust /ID# 244673, Gillingham, Kent, United Kingdom

and more 12 locations

Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy

Recruiting

Conditions: Migraine

First Posted Date: 2021-12-15

Last Posted Date: 2025-01-13

Lead Sponsor: AbbVie

Target Recruit Count: 1884

Registration Number: NCT05158894

Locations: 🇺🇸
Iqvia /Id# 266904, Durham, North Carolina, United States

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

Phase 4

Active, not recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2021-12-03

Last Posted Date: 2025-04-22

Lead Sponsor: AbbVie

Target Recruit Count: 44

Registration Number: NCT05144243

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 232253, Tianjin, Tianjin, China
🇨🇳
The First Affiliated Hospital of Wenzhou Medical University /ID# 233704, Wenzhou, Zhejiang, China
🇨🇳
Duplicate_The Affiliated Hospital of Guizhou Medical University /ID# 232465, Guiyang, China

and more 15 locations

Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Phase 2

Completed

Conditions: Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Interventions: Drug: BOTOX
Drug: Placebo for BOTOX

First Posted Date: 2021-12-02

Last Posted Date: 2025-05-06

Lead Sponsor: AbbVie

Target Recruit Count: 83

Registration Number: NCT05141006

Locations: 🇺🇸
Alliance for Multispecialty Research (AMR) - Mobile /ID# 241002, Mobile, Alabama, United States
🇺🇸
Urology Centers of Alabama /ID# 243600, Homewood, Alabama, United States
🇺🇸
Sun Kim Urology /ID# 257566, Buena Park, California, United States

and more 40 locations

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Phase 2

Active, not recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Biological: Lutikizumab
Drug: Placebo

First Posted Date: 2021-12-01

Last Posted Date: 2025-01-31

Lead Sponsor: AbbVie

Target Recruit Count: 210

Registration Number: NCT05139602

Locations: 🇨🇦
Dr. S.K. Siddha Medicine Professional Corporation /ID# 247986, Newmarket, Ontario, Canada
🇨🇦
Dre Angelique Gagne-Henley M.D. inc. /ID# 240739, Saint-Jerome, Quebec, Canada
🇦🇺
Momentum Clinical Research /ID# 240911, Darlinghurst, New South Wales, Australia

and more 51 locations

A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting

Recruiting

Conditions: Atopic Dermatitis

First Posted Date: 2021-12-01

Last Posted Date: 2025-04-18

Lead Sponsor: AbbVie

Target Recruit Count: 772

Registration Number: NCT05139836

Locations: 🇩🇪
Timmel/Timm/Vorwerk, Bergen /ID# 241661, Bergen, Germany
🇩🇪
Hautarztpraxis Dr. med. Christiane Handrick /ID# 262667, Berlin, Germany
🇩🇪
Praxis Dermatologie am Savigny /ID# 248846, Berlin, Germany

and more 122 locations

A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Phase 3

Completed

Conditions: Platysma Prominence

Interventions: Drug: OnabotulinumtoxinA

First Posted Date: 2021-11-26

Last Posted Date: 2024-12-05

Lead Sponsor: AbbVie

Target Recruit Count: 292

Registration Number: NCT05134649

Locations: 🇺🇸
Steve Yoelin MD Medical Assoc. Inc /ID# 232004, Newport Beach, California, United States
🇺🇸
Susan H. Weinkle MD /ID# 232001, Bradenton, Florida, United States
🇺🇸
Research Institute of the Southeast, LLC /ID# 231974, West Palm Beach, Florida, United States

and more 26 locations

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Phase 3

Conditions: Migraine

Interventions: Drug: Ubrogepant

First Posted Date: 2021-11-19

Last Posted Date: 2024-07-29

Lead Sponsor: AbbVie

Target Recruit Count: 1200

Registration Number: NCT05127954

Locations: 🇺🇸
Pediatrix Medical Group of Florida /ID# 233336, Winter Park, Florida, United States
🇺🇸
Centricity Research Columbus /ID# 238832, Columbus, Ohio, United States
🇺🇸
Houston Clinical Research Associates /ID# 246522, Houston, Texas, United States

and more 103 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy